Testing for acid load needed in patients with diabetes taking sodium-glucose cotransporter-2 inhibitors
Studies document renal benefits of canagliflozin, dapagliflozin, empagliflozin, and dulaglutide
In a phase 2 study of patients with early diabetic nephropathy, esaxerenone decreased microalbuminuria in a dose-dependent manner over 12 weeks compared with placebo.
In the REWIND trial of type 2 diabetes patients, dulaglutide modestly reduced cardiovascular events and progression of kidney disease for at least 5 years.
Ertugliflozin may be protective of renal function in patients with type 2 diabetes.
Type 1 diabetes onset before the age of 14 years is independently associated with a greater risk of kidney disease compared with later age at onset, according to a new study.
Protective effect is driven largely by a sustained 40% decrease in estimate glomerular filtration rate to below 60 mL/min/1.73 m2.
Per the ADA update, clinicians should consider prescribing a SGLT2 inhibitor in type 2 diabetes patients with diabetic nephropathy.
Undiagnosed chronic kidney disease is present in 49% of patients with type 2 diabetes mellitus in the United States, a study found.
Reduced risk seen for primary composite renal end point event; more frequent fluid retention, anemia reported